간흡충 치료 시장 : 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Liver Fluke Treatment Market was valued at USD 642.7 million in 2025 and is estimated to grow at a CAGR of 5% to reach USD 1 billion by 2035.

The market is witnessing steady growth driven by the rising incidence of parasitic infections affecting both human and animal populations across various regions. Increasing emphasis on early diagnosis and improved treatment outcomes is strengthening demand for effective therapeutic solutions. Advancements in diagnostic technologies, including molecular-based testing methods, have significantly enhanced early detection capabilities, enabling timely intervention and improved disease management. Additionally, growing investments in healthcare infrastructure and pharmaceutical research activities are supporting the development of advanced treatment options and improved therapeutic protocols. Preventive healthcare practices are also gaining traction in high-risk regions, further contributing to market expansion. The overall industry outlook remains positive, supported by continuous innovation in drug development, increasing awareness, and stronger veterinary and human healthcare integration.

Liver fluke treatment involves medical and veterinary approaches aimed at diagnosing and eliminating parasitic infections caused by trematode organisms that affect the liver and associated organs. These infections can lead to significant health complications if left untreated, impacting both humans and livestock. Treatment strategies typically include antiparasitic medications, supportive care, and preventive measures designed to control infection spread and manage associated symptoms. The market is characterized by the presence of several established pharmaceutical companies that focus on developing effective therapeutic solutions and expanding global access to treatment options.

The triclabendazole segment generated USD 266.4 million in 2025. This dominance is supported by its proven effectiveness in treating liver fluke infections, particularly in regions where such conditions are more prevalent. The drug's strong safety profile and high therapeutic efficacy have contributed to its widespread adoption in both human and veterinary applications. Its affordability further enhances accessibility, especially in regions with limited healthcare resources, making it a preferred treatment option for large-scale use.

The tablets segment accounted for 41.4% share in 2025, driven by its practicality and ease of administration. Tablets are widely preferred due to their stability, extended shelf life, and minimal storage requirements, making them suitable for distribution across diverse geographical regions. Improvements in pharmaceutical formulation have enhanced drug absorption and effectiveness, supporting better treatment outcomes. Established regulatory frameworks across multiple regions have further facilitated the approval and availability of tablet-based therapies, strengthening their adoption in global markets.

North America Liver Fluke Treatment Market was valued at USD 261.8 million in 2025, reflecting steady regional demand supported by strong healthcare and veterinary systems. The presence of a well-developed livestock industry significantly contributes to the need for effective parasite control measures to safeguard productivity and animal health. Continuous advancements in pharmaceutical research and the availability of established treatment options further support market growth. Increased awareness among healthcare professionals and livestock managers has also encouraged routine preventive and therapeutic interventions, reinforcing regional market stability.

Key companies operating in the Global Liver Fluke Treatment Market include Merck, Bayer Healthcare, Novartis, Virbac, GlaxoSmithKline, Pfizer, Vetoquinol, AdvaCare Pharma, Lupin Pharma, Schering Corporation, Par Pharmaceutical, and Zoetis. Companies in the Liver Fluke Treatment Market are focusing on research-driven innovation, portfolio expansion, and strategic partnerships to strengthen their market position. Continuous investment in drug development is enabling the introduction of more effective and safer therapeutic solutions. Firms are expanding their geographic reach through strengthened distribution networks to improve product accessibility across both developed and emerging regions. Collaboration with veterinary and healthcare institutions is supporting better awareness and adoption of treatment protocols. Additionally, companies are emphasizing affordability and accessibility to address demand in resource-constrained regions. Ongoing advancements in diagnostic and treatment technologies, combined with targeted marketing strategies, are further enhancing competitive positioning and long-term market sustainability.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Business trends
  • 2.2.2 Regional trends
  • 2.2.3 Drug type trends
  • 2.2.4 Formulation type trends
  • 2.2.5 Application trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of liver fluke infections
    • 3.2.1.2 Advancements in diagnostic techniques
    • 3.2.1.3 Growing livestock industry
    • 3.2.1.4 Availability of effective therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from alternative treatments
    • 3.2.2.2 Resistance to commonly used anthelmintic drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growth in veterinary preventive care and herd management solutions
    • 3.2.3.2 Expansion in emerging and underserved markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Pipeline analysis
• 3.8 Impact of AI and Generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Triclabendazole
• 5.3 Praziquantel
• 5.4 Bithionol
• 5.5 Albendazole
• 5.6 Nitazoxanide
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Injections
• 6.4 Oral suspension

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Human
• 7.3 Animals

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Veterinary facilities
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Bayer Healthcare
• 10.3 GlaxoSmithKline
• 10.4 Lupin Pharma
• 10.5 Merck
• 10.6 Novartis
• 10.7 Par Pharmaceutical
• 10.8 Pfizer
• 10.9 Schering Corporation
• 10.10 Vetoquinol
• 10.11 Virbac
• 10.12 Zoetis